![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1481281
Á¤¸Æ³» ¿ë¾× ½ÃÀå : À¯Çüº°, Á¶¼ºº°, ¿¬·ÉÃþº°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, ¼¼°è ¿¹Ãø(2024-2032³â)Intravenous Solutions Market - By Type (Total, Peripheral Parenteral Nutrition), Composition (Carbohydrates, Vitamins & Minerals, Single-dose Amino Acids, Parenteral Lipid Emulsion), Age Group, Application, End-user, Global Forecast, 2024 - 2032 |
¼¼°èÀÇ Á¤¸Æ³» ¿ë¾×ÀÇ ½ÃÀå Á¡À¯À²Àº Áö¼ÓÀû ¿¬±¸°³¹ß¿¡ ÀÇÇØ Áö¿øµÇ¾î 2024-2032³â 7.5%ÀÇ CAGRÀ» ±â·ÏÇÕ´Ï´Ù.
ÀÇÇÐÀÌ ¹ßÀüÇÔ¿¡ µû¶ó ¼ö¾×, ÀüÇØÁú ¹× ¾à¹°À» Ç÷·ù¿¡ Á÷Á¢ È¿°úÀûÀ¸·Î °ø±ÞÇØ¾ß ÇÒ Çʿ伺ÀÌ Á¡Á¡ ´õ Ä¿Áö°í ÀÖ½À´Ï´Ù.
¿¹¸¦ µé¾î 2023³â 11¿ù, ÃÖ±Ù ¸ÞŸºÐ¼®À» ÅëÇØ ÀϹÝÀûÀ¸·Î »ç¿ëµÇ´Â ½Ä¿°¼ö ´ë½Å ±ÕÇü ÀâÈù ¼ö¾× ¿ä¹ýÀ» ½ÃÇàÇϸé ÁßÁõ ȯÀÚÀÇ º´¿ø³» »ç¸Á À§ÇèÀ» 4% °¨¼Ò½Ãų ¼ö ÀÖ´Ù´Â »ç½ÇÀÌ ¹àÇôÁ³½À´Ï´Ù. ij³ª´Ù ÁßȯÀÚ Ä¡·á Æ÷·³(CCCF2023)¿¡¼ ¹ßÇ¥µÇ°í µ¿½Ã¿¡ The Lancet Respiratory Medicine Àú³Î¿¡ °ÔÀçµÈ BEST-Living StudyÀÇ ¿¬±¸ °á°ú´Â ȯÀÚ ¿¹ÈÄ¿¡ Å« ¿µÇâÀ» ¹ÌĨ´Ï´Ù´Â °ÍÀ» º¸¿©ÁÝ´Ï´Ù. À¯¸íÇÑ ÁýÁßÄ¡·á Àü¹®ÀÇÀÌÀÚ The George Institute for Global HealthÀÇ Àü¹® Æç·Î¿ìÀÎ Simon Finfer AO ±³¼ö´Â ÁýÁßÄ¡·á¿¡¼ ¼ö¾× ¼±ÅÃÀÇ Á߿伺À» °Á¶Çß½À´Ï´Ù.
Á¦¾à Á¦Á¦ ¹× ÀÇ·á ±â¼ú ºÐ¾ßÀÇ ²÷ÀÓ¾ø´Â Çõ½ÅÀº ƯÁ¤ ȯÀÚÀÇ ¿ä±¸¿¡ ¸Â´Â »õ·Î¿î Á¤¸Æ³» ¿ë¾×ÀÇ °³¹ßÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ȯÀÚ °á°ú °³¼±°ú ÀÇ·á ¼ºñ½º °È¿¡ ÁßÁ¡À» µÐ Á¤¸Æ³» ¿ë¾×¿¡ ´ëÇÑ ¼ö¿ä´Â ÀÇ·á »ê¾÷ÀÇ ¿ªµ¿ÀûÀΠƯ¼ºÀ» ¹Ý¿µÇÏ¿© Áö¼ÓÀûÀ¸·Î ¼ºÀåÇϰí ÀÖ½À´Ï´Ù.
2024-2032³â ¸»ÃÊ¿µ¾çÇÐ ºÐ¾ß´Â Å« ¹ßÀüÀ» ÀÌ·ê °ÍÀ¸·Î ¿¹»óµÇ¸ç, PPNÀº °æ±¸ ¿µ¾ç ¼·Ãë°¡ ¾î·Á¿î ȯÀÚ¿¡°Ô Çʼö ¿µ¾ç¼Ò¸¦ °ø±ÞÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϸç, PPN¿¡ ¸Â°Ô Á¶Á¤µÈ Á¤¸Æ³» ¿ë¾×Àº Çʼö ¿µ¾ç¼Ò¸¦ Ç÷·ù·Î Á÷Á¢ °ø±ÞÇÏ¿© ¿µ¾ç½ÇÁ¶¿¡ ´ëóÇϰí ȯÀÚÀÇ È¸º¹À» µ½½À´Ï´Ù. ¿µ¾ç °áÇÌÀ» ÇØ°áÇϰí ȯÀÚÀÇ È¸º¹À» µ½½À´Ï´Ù. ÀÇ·á ¼ºñ½º ÇÁ·Î¹ÙÀÌ´õµéÀÌ ´Ù¾çÇÑ ÀÓ»ó ÇöÀå¿¡¼ PPNÀÇ ÀÌÁ¡À» ÀνÄÇÔ¿¡ µû¶ó Ư¼ö Á¤¸Æ³» ¿ë¾×¿¡ ´ëÇÑ ¼ö¿ä´Â Áö¼ÓÀûÀ¸·Î Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå È®´ëÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù.
ºñŸ¹Î ¹× ¹Ì³×¶ö ºÐ¾ßÀÇ Á¤¸Æ³» ¿ë¾× ½ÃÀå Á¡À¯À²Àº 2024-2032³â ÁÖ¸ñÇÒ ¸¸ÇÑ CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ¼Ö·ç¼ÇÀº ƯÈ÷ Èí¼ö Àå¾Ö°¡ Àְųª °æ±¸¿ë º¸ÃæÁ¦¸¦ º¹¿ëÇÒ ¼ö ¾ø´Â ȯÀڵ鿡°Ô Çʼö ¿µ¾ç¼Ò¸¦ Ç÷·ù·Î Á÷Á¢ °ø±ÞÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ÀÇ·á ¼ºñ½º ÇÁ·Î¹ÙÀÌ´õ°¡ ȯÀÚÀÇ ÃÖÀûÀÇ ¿µ¾ç°ú °Ç°À» ¿ì¼±½ÃÇÏ´Â °¡¿îµ¥, ÀÇ·á ÇöÀå¿¡¼ Á¾ÇÕÀûÀÎ ¿µ¾ç Áö¿øÀÇ Á߿伺À» ¹Ý¿µÇÏ¿© ºñŸ¹Î ¹× ¹Ì³×¶ö °È Á¤¸Æ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áö¼ÓÀûÀ¸·Î Áõ°¡Çϰí ÀÖ½À´Ï´Ù.
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Á¤¸Æ³» ¿ë¾× ½ÃÀåÀº 2024-2032³â »ó´çÇÑ CAGRÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÇ·á ÀÎÇÁ¶óÀÇ È®´ë¿Í ¸¸¼ºÁúȯ Áõ°¡·Î ÀÎÇØ Áß¿äÇÑ ¼öºÐ, ÀüÇØÁú ¹× ¾à¹°À» °ø±ÞÇϱâ À§ÇÑ Á¤¸Æ³» ¿ë¾×¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀÇ ÀÇ·á ºÎ¹®Àº ȯÀÚ °ü¸®¿Í Ä¡·á¿¡ ÀÖÀ¸¸ç, Á¤¸ÆÁÖ»ç ¿ä¹ýÀÇ Á߿伺À» °Á¶Çϰí ÀÖ½À´Ï´Ù. Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Á¤¸ÆÁÖ»çÁ¦ ¼ö¿ä´Â Á¤ºÎ¿Í ÀÇ·á ¼ºñ½º ÇÁ·Î¹ÙÀÌ´õµéÀÌ ÀÇ·á ¼ºñ½º Á¢±Ù¼º ¹× ǰÁú Çâ»óÀ» ¿ì¼±¼øÀ§·Î »ïÀ¸¸é¼ Áö¼ÓÀûÀ¸·Î Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.
¿¹¸¦ µé¾î 2023³â 11¿ù īŸ¸£ ÀÚ¼±´Üü´Â ¼ö´ÜÀÇ ÀÇ·á ºÎ¹®À» °ÈÇϱâ À§ÇÑ Áö¼ÓÀûÀÎ ³ë·ÂÀÇ ÀÏȯÀ¸·Î Á¤¸ÆÁÖ»çÁ¦ °ø±ÞÀ» ÅëÇØ Áö¿øÀ» È®´ëÇß½À´Ï´Ù. ÀÌ ´Üü´Â ÃÖ±Ù ¾ËÀÚÁö¶ó(Al Jazeera)¿Í °Ô´Þ·¹ÇÁ(Gedalef) ÁÖ¿¡ ÀÖ´Â º¸°Ç ¹× ÀεµÀû Áö¿ø ±â°ü¿¡ ÀÌ Áß¿äÇÑ ÀǾàǰÀ» º¸³Â½À´Ï´Ù. ±× ¸ñÀûÀº ÀÌ Áö¿ª¿¡¼ À¯ÇàÇÏ´Â µ±â¿°ú ¼³»ç¿Í °°Àº °Ç° ¹®Á¦¸¦ ÅðÄ¡ÇÏ´Â µ¥ µµ¿òÀ» ÁÖ±â À§ÇÔÀÔ´Ï´Ù.
Global Intravenous Solutions Market share will witness 7.5% CAGR between 2024 and 2032, propelled by ongoing research and developments. As medical science advances, the need for effective delivery of fluids, electrolytes, and medications directly into the bloodstream becomes increasingly crucial.
For instance, in November 2023, A recent meta-analysis revealed that using balanced solutions of intravenous fluid (IV) therapy, rather than the commonly used saline, may reduce the risk of in-hospital death among critically ill patients by 4%. Presented at the Critical Care Canada Forum (CCCF 2023) and concurrently published in The Lancet Respiratory Medicine, the findings from the BEST-Living Study indicate a significant impact on patient outcomes. Professor Simon Finfer AO, a renowned Intensive Care physician and Professorial Fellow at The George Institute for Global Health, emphasized the importance of IV fluid selection in intensive care treatment.
Continuous innovations in pharmaceutical formulations and medical technology drive the development of new intravenous solutions tailored to specific patient needs. With a focus on improving patient outcomes and enhancing healthcare delivery, the demand for intravenous solutions continues to grow, reflecting the dynamic nature of the healthcare industry.
The overall Intravenous Solutions Industry size is classified based on the type, composition, age group, application, end-user, and region.
The peripheral parental nutrition segment will undergo significant development from 2024 to 2032. PPN plays a vital role in providing essential nutrients to patients who can not consume adequate nutrition orally. Intravenous solutions tailored for PPN deliver essential nutrients directly into the bloodstream, addressing malnutrition and supporting patient recovery. As healthcare providers recognize the benefits of PPN in various clinical settings, the demand for specialized intravenous solutions continues to grow, driving market expansion.
The intravenous solutions market share from the vitamins and minerals segment will register a noteworthy CAGR from 2024 to 2032. These solutions play a critical role in delivering essential nutrients directly into the bloodstream, particularly for patients with malabsorption issues or those unable to consume oral supplements. As healthcare providers prioritize optimal patient nutrition and wellness, the demand for intravenous solutions enriched with vitamins and minerals continues to grow, reflecting the importance of comprehensive nutritional support in healthcare settings.
MEA intravenous solutions market will showcase a commendable CAGR from 2024 to 2032. With expanding healthcare infrastructure and the rising prevalence of chronic diseases, there's a growing need for intravenous solutions to deliver vital fluids, electrolytes, and medications. The region's healthcare sector is emphasizing the importance of intravenous therapy for patient management and treatment. As governments and healthcare providers prioritize improving healthcare access and quality, the demand for intravenous solutions in the MEA region continues to rise, driving market growth.
For instance, in November 2023, in an ongoing effort to bolster Sudan's healthcare sector, Qatar Charity extended support by supplying intravenous solutions. The organization recently dispatched shipments of these vital medical supplies to health and humanitarian agencies in Al-Jazeera and Gedaref states. The aim is to assist in combating prevalent health challenges like dengue fever and diarrhea in the region.